18F-fluorodeoxyglucose positron-emission tomography-computed tomography to diagnose recurrent cancer
Authors:
Open Access
- 5 May 2015
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 112 (11) , 1737-1743
Abstract
Background: Sometimes the diagnosis of recurrent cancer in patients with a previous malignancy can be challenging. This prospective cohort study assessed the clinical utility of 18F-fluorodeoxyglucose positron-emission tomography-computed tomography (18F-FDG PET-CT) in the diagnosis of clinically suspected recurrence of cancer. Methods: Patients were eligible if cancer recurrence (non-small-cell lung (NSCL), breast, head and neck, ovarian, oesophageal, Hodgkin’s or non-Hodgkin’s lymphoma) was suspected clinically, and if conventional imaging was non-diagnostic. Clinicians were asked to indicate their management plan before and after 18F-FDG PET-CT scanning. The primary outcome was change in planned management after 18F-FDG PET-CT. Results: Between April 2009 and June 2011, 101 patients (age, median 65 years; 55% female) were enroled from four cancer centres in Ontario, Canada. Distribution by primary tumour type was: NSCL (55%), breast (19%), ovarian (10%), oesophageal (6%), lymphoma (6%), and head and neck (4%). Of the 99 subjects who underwent 18F-FDG PET-CT, planned management changed after 18F-FDG PET-CT in 52 subjects (53%, 95% confidence interval (CI), 42–63%); a major change in plan from no treatment to treatment was observed in 38 subjects (38%, 95% CI, 29–49%), and was typically associated with 18F-FDG PET-CT findings that were positive for recurrent cancer (37 subjects). After 3 months, the stated post-18F-FDG PET-CT management plan was actually completed in 88 subjects (89%, 95% CI, 81–94%). Conclusion: In patients with suspected cancer recurrence and conventional imaging that is non-diagnostic, 18F-FDG PET-CT often provides new information that leads to important changes in patient management.Keywords
This publication has 16 references indexed in Scilit:
- Intended Versus Inferred Care After PET Performed for Initial Staging in the National Oncologic PET RegistryJournal of Nuclear Medicine, 2013
- Evidence-Based Approach to the Introduction of Positron Emission Tomography in Ontario, CanadaJournal of Clinical Oncology, 2009
- Impact of Positron Emission Tomography/Computed Tomography and Positron Emission Tomography (PET) Alone on Expected Management of Patients With Cancer: Initial Results From the National Oncologic PET RegistryJournal of Clinical Oncology, 2008
- Diagnostic and Prognostic Value of 18F-FDG PET/CT for Patients with Suspected Recurrence from Squamous Cell Carcinoma of the EsophagusJournal of Nuclear Medicine, 2007
- Early detection of cancer recurrence: 18F-FDG PET/CT can make a difference in diagnosis and patient care.2007
- FDG-PET in the detection of residual disease and relapse in patients with Hodgkin's lymphoma. Experience from a Swedish centre.Acta Oncologica, 2006
- Evaluation of integrated whole-body PET/CT in the detection of recurrent ovarian cancerEuropean Journal of Radiology, 2005
- A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastasesBreast Cancer Research and Treatment, 2005
- Annual Report to the Nation on the status of cancer, 1973–1999, featuring implications of age and aging on U.S. cancer burdenCancer, 2002
- Comparison of 18FDG-PET with CT scans in the evaluation of patients with residual and recurrent Hodgkin's lymphomaOncology Reports, 2001